PMID- 32963409
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210110
IS  - 0001-4079 (Print)
IS  - 2271-4820 (Electronic)
IS  - 0001-4079 (Linking)
VI  - 204
IP  - 9
DP  - 2020 Dec
TI  - [The next psychoactive drugs: From imipramine to ketamine].
PG  - 1034-1042
LID - 10.1016/j.banm.2020.09.038 [doi]
AB  - Since the 1950s, the therapeutic arsenal against depression has grown 
      considerably. From the discovery of monoamine oxidase inhibitors (MAOI) to the 
      antidepressant effect of ketamine, these pharmacological breakthroughs made the 
      history of psychiatry. They also guided the research about the pathophysiology of 
      depression, one of the most devasting diseases, which affects between 10 and 20 % 
      of general population. In this article, we offer a short historical review of the 
      various therapeutic options developed over the past century and the consequences 
      of these innovations. We then review the most recent one, ketamine (and its 
      enantiomer S, esketamine). Ketamine's effects are spectacular both in terms of 
      their very short onset time, and because they are observed even in 
      treatment-resistant depression. Just as MAOIs and tricyclic antidepressants 
      allowed the "monoaminergic hypothesis of depression" to emerge, to unravel the 
      mechanisms of ketamine's antidepressant effects should allow the understanding of 
      the role of glutamatergic system, or that of neuro-inflammation, in the 
      neurobiology of depression. Ketamine might also help to refine our understanding 
      of the cognitive pathophysiology of depression, or even to deeply transform the 
      clinical representations about what depression is.
CI  - (c) 2020 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All 
      rights reserved.
FAU - Carrillo, P
AU  - Carrillo P
AD  - Departement de psychiatrie, centre hospitalier le Vinatier, 69678 Bron, France.
FAU - Petit, A-C
AU  - Petit AC
AD  - Universite de Paris, 75006 Paris, France.
AD  - Service hospitalo-universitaire, GHU Paris psychiatrie & neurosciences, 75014 
      Paris, France.
AD  - Unite de neuropathologie experimentale, departement sante globale, Institut 
      Pasteur, 75015 Paris, France.
FAU - Gaillard, R
AU  - Gaillard R
AD  - Universite de Paris, 75006 Paris, France.
AD  - Service hospitalo-universitaire, GHU Paris psychiatrie & neurosciences, 75014 
      Paris, France.
AD  - Unite de neuropathologie experimentale, departement sante globale, Institut 
      Pasteur, 75015 Paris, France.
FAU - Vinckier, F
AU  - Vinckier F
AD  - Universite de Paris, 75006 Paris, France.
AD  - Service hospitalo-universitaire, GHU Paris psychiatrie & neurosciences, 75014 
      Paris, France.
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Psychotropes du futur : de l'imipramine a la ketamine.
DEP - 20200917
PL  - Netherlands
TA  - Bull Acad Natl Med
JT  - Bulletin de l'Academie nationale de medecine
JID - 7503383
PMC - PMC7494514
OTO - NOTNLM
OT  - Antidepressant
OT  - Depression
OT  - Ketamine
OT  - Neuro-inflammation
OT  - Psychiatry
EDAT- 2020/09/24 06:00
MHDA- 2020/09/24 06:01
PMCR- 2020/09/17
CRDT- 2020/09/23 06:33
PHST- 2020/02/15 00:00 [received]
PHST- 2020/09/10 00:00 [accepted]
PHST- 2020/09/24 06:00 [pubmed]
PHST- 2020/09/24 06:01 [medline]
PHST- 2020/09/23 06:33 [entrez]
PHST- 2020/09/17 00:00 [pmc-release]
AID - S0001-4079(20)30512-4 [pii]
AID - 10.1016/j.banm.2020.09.038 [doi]
PST - ppublish
SO  - Bull Acad Natl Med. 2020 Dec;204(9):1034-1042. doi: 10.1016/j.banm.2020.09.038. 
      Epub 2020 Sep 17.